3CL^pro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.

ABSTRACT:

SUBMITTER: Sisay M 

PROVIDER: S-EPMC7128271 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature